Abstract:
A quick release weapon mount is provided, the mount comprising a housing member having a base and a means for attaching an accessory, and at least one clamp. The clamp comprising one or more slideably engaged translational members, wherein the translational members are adapted for slideable translational-movement. The means for attaching an accessory can include a lumen, a clamping band, a toggle clamp, a spring clip, a latch or other attachment means. An additional translational clamp can be included to lock an accessory in a fixed axial position on the mount. The mount can further include a supplemental accessory rail for modular construction of several accessories and a safety mechanism for preventing premature release of the mount.
Abstract:
A bar-b-que grill comprising: a front wall; a first side wall in communication with the front wall; a rear wall in communication with the first side wall; a second side wall in communication with the front wall and the rear wall; a first slot located in the first side wall; a second slot located in the second side wall; a first U shaped rail in communication with the front wall, with an opening of the U facing towards the rear wall; a second U shaped rail in communication with the rear wall, with an opening of the U facing towards the front wall; at least one heat deflector plate, wherein the first and second U shaped rails are configured to allow the at least one heat deflector plate to slide along the first and second U shaped rails into and out of the bar-b-que grill via at least one of the first and second slots.
Abstract:
A novel method has led to the identification of novel mixed ester-amidates of PMPA for retroviral or hepadnaviral therapy, including compounds of structure (5a) having substituent groups as defined herein. Compositions of these novel compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided.
Abstract:
A novel method has led to the identification of novel mixed ester-amidates of PMPA for retroviral or hepadnaviral therapy, including compounds of structure (5a) having substituent groups as defined herein. Compositions of these novel compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided.
Abstract:
An airline may offer two procedures for redeeming frequent flier miles for tickets on a specified flight of that airline, with one procedure available to frequent flier program members that do not have transactional cards associated with the frequent flier program, and another redemption procedure available to frequent flier program members that have a transactional card associated with the frequent flier program. Cardmembers have improved award seat availability for frequent flier mile redemption, regardless of their status in the frequent flier program. Cardmembers are provided with last seat availability at a base redemption rate. Thus, cardmembers are not subject to limited award seat capacity controls and restrictions that airline frequent flier programs have in place, and cardmembers do not have to use higher redemption rates for last seat availability.
Abstract:
A novel method has led to the identification of novel mixed ester-amidates of PMPA for retroviral or hepadnaviral therapy, including compounds of structure (5a) having substituent groups as defined herein. Compositions of these novel compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided.
Abstract:
A novel method has led to the identification of novel mixed ester-amidates of PMPA for retroviral or hepadnaviral therapy, including compounds of structure (5a) having substituent groups as defined herein. Compositions of these novel compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided.
Abstract:
A novel method has led to the identification of novel mixed ester-amidates of PMPA for retroviral or hepadnaviral therapy, including compounds of structure (5a) having substituent groups as defined herein. Compositions of these novel compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided.
Abstract:
An electrical connecting module includes a first electrical connection terminal with a first connection pole and a second connection pole; a module element with a second electrical connection terminal, which comprises a first connection pole and a second connection pole, and with a third electrical connection terminal, which comprises a first connection pole and a second connection pole. A test channel is provided for accommodating a test probe. wherein the test channel is intended for making electrical contact with the second connection pole of the first connection terminal by means of the test probe when there is an electrical connection between the first connection pole of the first connection terminal and the first connection pole of the third connection terminal and when the electrical connection between the second connection pole of the first connection terminal and the second connection pole of the third connection terminal is disconnected.
Abstract:
Phosphonate substituted compounds with HIV protease inhibitory properties having use as therapeutics and for other industrial purposes are disclosed. The compositions inhibit HIV protease activity and/or are useful therapeutically for the treatment of AIDS and other antiviral infections, as well as in assays for the detection of HIV protease.